Loading…
Loading…
State Council Order No. 818 was adopted by the 68th Standing Meeting of the State Council on 12 September 2025 and promulgated on 28 September 2025. It entered into force on 1 May 2026. The regulation operates as a parent statute for China's entire post-2026 cell-and-gene therapy (CGT) regulatory cohort, establishing the administrative framework within which NHC and NMPA issue implementing technical guidance.
Dual-track architecture. Pre-Order 818, China had a single pathway for biomedical product commercialisation: full NMPA drug/device registration, a 5–8 year process. Order 818 adds a second parallel pathway:
1. NHC clinical-research track (Articles 4–28): Clinical studies in "biomedical new technologies" require approval from a Grade-3A medical institution's academic review committee and ethics committee, registration with NHC within 5 working days, and no patient fees during the research phase. NHC maintains a Filing Guidance List defining eligible technology categories. Participants are protected under informed consent and data-privacy provisions.
2. NHC clinical-translation/commercialisation track (Articles 29–42): Technologies demonstrating consistent safety and efficacy across multi-centre studies become eligible for fee-based commercial use within approved institutions — without requiring full NMPA registration — if they qualify as either (a) highly personalised therapies where no similar-mechanism drug has obtained marketing authorisation or initiated confirmatory trials in China, or (b) rare-disease treatments where no similar drug has reached Phase III domestically. Commercialisation periods are risk-stratified: 5 years for high-risk, 3 years for medium-risk, 1 year for low-risk technologies, after which full NMPA registration is required for continuation.
Institutional scope. Clinical research and translation activities are restricted to Grade-3A (三级甲等) hospitals with qualifying clinical-research academic committees, ethics committees, and proportional R&D infrastructure. This concentrates early CGT commercialisation in China's ~1,500 Grade-3A hospitals, limiting availability to tier-1 and tier-2 cities in the near term.
Supervisory architecture. NHC retains authority over the clinical-research and clinical-translation stages. NMPA is consulted on classification decisions (whether a technology's mechanism is "similar" to an approved drug, which determines pathway eligibility). The China National Center for Biotechnology Development (CNCBD) provides technical evaluation support and manages human-genetic-resources oversight requirements for studies involving sample collection.
(Legend Biotech / J&J cilta-cel CARVYKTI, Gracell / AstraZeneca FasTCAR, Innovent / Eli Lilly equivalents, Adagene / Roche bispecific antibodies) were structured under the NMPA single-pathway assumption. The new NHC commercialisation track introduces a materially faster route for "highly personalised" therapies that restructures milestone-payment timelines, regulatory-risk allocations, and royalty-stream onset in existing and prospective licensing agreements.
commercial access for qualifying therapies without full NMPA approval — potentially opening patient populations 5–8 years earlier. Conversely, Chinese CGT developers leveraging Order 818's NHC track accumulate institutional real-world evidence data that may later support NMPA registration and global regulatory submissions (EMA, FDA), compressing the international development timeline for Chinese-origin therapies.
filed separately) restricts US federal procurement from entities including WuXi AppTec and WuXi Biologics. Order 818 creates new demand for Chinese CDMO and clinical-services capacity within China's Grade-3A hospital network, partially insulating the domestic CGT supply chain from BIOSECURE-driven contract-manufacturing diversification pressure.
resource collection to comply with the 2019 HGR Regulations and NHC implementing rules. This intersects with the May 2026 NHC HGR Implementation Rules consultation draft (pending filing) that proposes to relax cross-border genomic-data sharing restrictions.
for stem-cell IND-vs-IIT classification) defining the "Filing Guidance List" categories that gate NHC-track eligibility for specific technology platforms.
registration at expiry or allow renegotiated NHC-track extensions.
(NHSA) — therapies commercialised without full NMPA registration are likely ineligible for national reimbursement lists, limiting payer coverage to institutional self-pay or commercial insurance in the near term.
domestic and international CGT pipelines — the NHC track may accelerate China launches but create regulatory divergence requiring parallel NMPA filings for global programmes.